Donanemab
(Synonyms: LY3002813) 目录号 : GC68996Donanemab是一种人源化IgG1单克隆抗体。Donanemab靶向沉积的Aβ42，并通过小胶质细胞介导的吞噬作用清除脑内淀粉样斑块。Donanemab主要定位于血浆和细胞外空间，并可穿过血脑屏障进入脑部与Aβ沉积物结合。Donanemab是治疗阿尔茨海默病的有效药物 。
Cas No.:1931944-80-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Donanemab is a humanized IgG1 monoclonal antibody. Donanemab targets deposited Aβ42, and clear amyloid plaques in the brain through microglia-mediated phagocytosis. Donanemab mainly localized in the plasma and extracellular space and penetrates the brain across the blood–brain barrier to bind Aβ deposits. Donanemab is an effective treatment for Alzheimer's disease [1-5].
In the platelet-derived growth factor promoter-amyloid precursor protein (PDAPP) mouse model, Aβ42 levels in the hippocampus and cortex of mice were significantly reduced after Donanemab (1.5, 4, and 12.5mg/kg; sc; 6 months) treatment [6].
References:
[1]. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. Jama. 2023 Aug 8; 330(6): 512-527.
[2]. Mintun M, Ritchie CW, Solomon P, et al. Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial. Alzheimer's & Dementia. 2023 Dec; 19: e082733.
[3]. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. New England Journal of Medicine. 2021 May 6; 384(18): 1691-1704.
[4]. Jayaprakash N, Elumalai K. Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application. Chronic Diseases and Translational Medicine. 2024.
[5]. Kang C. Donanemab: first approval. Drugs. 2024 Oct; 84(10): 1313-1318.
[6]. DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron. 2012 Dec 6; 76(5): 908-920.
Donanemab是一种人源化IgG1单克隆抗体。Donanemab靶向沉积的Aβ42，并通过小胶质细胞介导的吞噬作用清除脑内淀粉样斑块。Donanemab主要定位于血浆和细胞外空间，并可穿过血脑屏障进入脑部与Aβ沉积物结合。Donanemab是治疗阿尔茨海默病的有效药物 [1-5]。
在血小板衍生生长因子启动子驱动的淀粉样前体蛋白转基因小鼠模型中，Donanemab（1.5、4和12.5 mg/kg；sc；6个月）治疗后，小鼠的海马和皮质中的Aβ42水平显著降低 [6]。
| Animal experiment [1]: | |
Animal models | Platelet-derived growth factor promoter-amyloid precursor protein (PDAPP) mouse model |
Preparation Method | PDAPP mice were injected subcutaneously weekly for 6 months with 1.5, 4, and 12.5mg/kg of Donanemab. |
Dosage form | 1.5, 4, and 12.5mg/kg; sc; 6 months |
Applications | PDAPP mice treated with the Donanemab antibody showed a significant dose-dependent decrease in Aβ42 levels in both the hippocampus and cortex. |
References: | |
| Cas No. | 1931944-80-7 | SDF | Download SDF |
| 别名 | LY3002813 | ||
| 分子式 | 分子量 | ||
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet